Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
3 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
Fastest customizable press release news feed in the world
Jonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical OfficerViridian is developing VRDN-001 and VRDN-002 for the treatment of thyroid eye diseaseCompany recently licensed exclusive rights from Xencor, Inc. to develop and commercialize therapeutic antibodies targeting IGF-1R incorporating Xtend™ Fc half-life extension technology BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics, Inc. (“Viridian”). Beginning tomorrow, Viridian will trade on NASDAQ under the ticker symbol "VR
Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor’s Xtend™ half-life extension technology miRagen expects to file an Investigational New Drug (IND) application for VRDN-002, including half-life extension, by the end of 2021 BOULDER, Colo., Dec. 17, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced an agreement under which miRagen gains exclusive rights to develop and commercialize therapeutic antibodies targeting IGF-1R incorporating Xtend™ Fc technology from Xencor, Inc. This clinically validated technology p
8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
SC 13G - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
4 - MIRAGEN THERAPEUTICS, INC. (0001590750) (Issuer)
SC 13G - MIRAGEN THERAPEUTICS, INC. (0001590750) (Subject)
SC 13G - MIRAGEN THERAPEUTICS, INC. (0001590750) (Subject)
SC 13G - MIRAGEN THERAPEUTICS, INC. (0001590750) (Subject)
SC 13D - MIRAGEN THERAPEUTICS, INC. (0001590750) (Subject)
8-K - MIRAGEN THERAPEUTICS, INC. (0001590750) (Filer)
424B5 - MIRAGEN THERAPEUTICS, INC. (0001590750) (Filer)
EFFECT - MIRAGEN THERAPEUTICS, INC. (0001590750) (Filer)
Live Leadership Updates
Jonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical OfficerViridian is developing VRDN-001 and VRDN-002 for the treatment of thyroid eye diseaseCompany recently licensed exclusive rights from Xencor, Inc. to develop and commercialize therapeutic antibodies targeting IGF-1R incorporating Xtend™ Fc half-life extension technology BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics, Inc. (“Viridian”). Beginning tomorrow, Viridian will trade on NASDAQ under the ticker symbol "VR
This live feed shows all institutional transactions in real time.
SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
SC 13G - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
SC 13G - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)